The underestimated role of somatostatin analogs in the NETTER-1 trial

Future Oncol. 2017 Jun;13(15):1287-1289. doi: 10.2217/fon-2017-0130. Epub 2017 May 11.

Authors

Sara Pusceddu¹, Roberto Buzzoni¹, Filippo de Braud^{2

1}

Affiliations

¹ University of Milan, Fondazione IRCCS "Istituto Nazionale dei Tumori", Via G. Venezian 1, 20133 Milan, Italy.
² Department of Medical Oncology Unit 1, GEP-ENETS Center of Excellence, "Istituto Nazionale Tumori", Milan, Italy.

PMID: 28492350
DOI: 10.2217/fon-2017-0130

No abstract available

Keywords: NETTER-1; PRRT; clinical trials; lanreotide; neuroendocrine tumors; octreotide; somatostatin analogs.

Publication types

Editorial
Comment

MeSH terms

Humans
Neuroendocrine Tumors*
Octreotide / analogs & derivatives
Organometallic Compounds*
Somatostatin

Substances

Organometallic Compounds
Somatostatin
lutetium Lu 177 dotatate
Octreotide